+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Thromboembolic adverse events after use of recombinant human coagulation factor VIIa



Thromboembolic adverse events after use of recombinant human coagulation factor VIIa



JAMA 295(3): 293-298



The US Food and Drug Administration (FDA) licensed recombinant human coagulation factor VIIa (rFVIIa) on March 25, 1999, for bleeding in patients with hemophilia A or B and inhibitors to factors VIII or IX. Use in patients without hemophilia has been increasing since licensure. To review serious thromboembolic adverse events (AEs) reported to the FDA's Adverse Event Reporting System (AERS). The AERS database was reviewed from March 25, 1999, through December 31, 2004, for thromboembolic AE reports with rFVIIa. The AERS database includes US and non-US spontaneous AE reports from both approved (specific indications for patients with hemophilia) and unlabeled uses. It also includes serious AEs in patients enrolled in postlicensure clinical trials who received rFVIIa. Manufacturer reporting to FDA is mandatory, but primary notification from clinicians and others to FDA or manufacturers is voluntary for spontaneous reports; therefore, AERS underrepresents actual event occurrences. Reported thromboembolic events occurring in patients administered rFVIIa. A total of 431 AE reports for rFVIIa were found, of which 168 reports described 185 thromboembolic events. Seventeen events occurred in patients with hemophilia and 59 occurred in patients enrolled in postlicensure trials. Unlabeled indications accounted for 151 of the reports, most with active bleeding (n = 115). Reported AEs were thromboembolic cerebrovascular accident (n = 39), acute myocardial infarction (n = 34), other arterial thromboses (n = 26), pulmonary embolism (n = 32), other venous thromboses (including deep vein thrombosis) (n = 42), and clotted devices (n = 10). In 36 (72%) of 50 reported deaths, the probable cause of death was the thromboembolic event. In 144 patients with timing information, 73 events (52%) occurred in the first 24 hours after the last dose (30 events within 2 hours). Sixty-four reports (38%) noted concomitant use of hemostatic agents. Most reports lacked sufficient information to evaluate potential dosage associations. Most reported thromboembolic AEs followed the use of rFVIIa for unlabeled indications and occurred in arterial and venous systems, often resulting in serious morbidity and mortality. Analysis of the relationship between AEs and rFVIIa is hindered by concomitant medications, preexisting medical conditions, confounding by indication, and inherent limitations of passive surveillance. Randomized controlled trials are needed to establish the safety and efficacy of rFVIIa in patients without hemophilia.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012693246

Download citation: RISBibTeXText

PMID: 16418464

DOI: 10.1001/jama.295.3.293


Related references

Thromboembolic Adverse Events After Use of Recombinant Human Coagulation Factor VIIa. Yearbook of Vascular Surgery 2008: 104-105, 2008

Recombinant factor VIIa and thromboembolic events. JAMA 296(1): 43-4; Author Reply 44, 2006

Whole blood coagulation in children with thrombocytopenia and the response to platelet replacement, recombinant factor VIIa, and a potent factor VIIa analogue. British Journal of Haematology 144(1): 99, 2009

Activated recombinant factor VIIa should not be used in patients with refractory variceal bleeding: it is mostly ineffective, is expensive, and may rarely cause serious adverse events. Hepatology 60(5): 1786-1788, 2014

Recombinant activated factor VII is associated with postoperative thromboembolic adverse events in bleeding after coronary surgery. Interactive Cardiovascular and Thoracic Surgery 27(3): 350-356, 2018

Recombinant activated factor VII in the treatment of non-haemophilia patients: physician under-reporting of thromboembolic adverse events. Transfusion Medicine 19(1): 43-49, 2009

Recombinant activated factor VII (rFVIIa) in the treatment of non-hemophilia patients: Physician underreporting of thromboembolic adverse events. 2007

Recombinant Nematode Anticoagulant Protein C2 , an Inhibitor of Tissue Factor/Factor VIIa, Attenuates Coagulation and the IL-10 Response in Human Endotoxemia. Blood 100(11): Abstract No 1892, 2002

Acidosis and impaired blood coagulation: what and how to correct before using recombinant human factor VIIa. Critical Care Medicine 35(6): 1627-1629, 2007

Recombinant nematode anticoagulant protein c2, an inhibitor of tissue factor/factor VIIa, attenuates coagulation and the interleukin-10 response in human endotoxemia. Journal of Thrombosis and Haemostasis 2(1): 65-70, 2004

Internalization and degradation of recombinant human coagulation factor VIIa by the human hepatoma cell line HuH7. Thrombosis and Haemostasis 73(2): 231-238, 1995

Effect of hemodilution on coagulation and recombinant factor VIIa efficacy in human blood in vitro. Journal of Trauma 71(5): 1152-1163, 2011

Recombinant human coagulation factor VIIa in Jehovah's Witness patients undergoing liver transplantation. American Surgeon 71(2): 175-179, 2005

Risk of thromboembolic events after protocolized warfarin reversal with 3-factor PCC and factor VIIa. American Journal of Emergency Medicine 33(11): 1562-1566, 2015

Inhibition of recombinant human blood coagulation factor VIIa amidolytic and proteolytic activity by zinc ions. Thrombosis and Haemostasis 65(5): 528-534, 1991